Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant announced that its Phase 3 clinical trials for batoclimab in treating thyroid eye disease (TED) failed to meet their primary efficacy endpoint. While safety profiles were consistent with previous results and no new risks identified, the drug did not achieve the targeted proptosis improvement at 24 weeks. The company highlighted promising…